The DOI matches its Crossref record; 36 of the 36 references it cites were found in a registry or an index.
mTOR kinase inhibitors promote antibody class switching via mTORC2 inhibition
Open accessAbstract
Significance: Rapamycin is an immunosuppressive drug that partially inhibits the cellular kinase mammalian target of rapamycin (mTOR). This study uncovers previously unidentified mechanisms of mTOR signaling in B cells. Antigen recognition and other signals activate mTOR, a central driver of lymphocyte proliferation and differentiation. However, mTOR forms two protein complexes (mTORC1 and mTORC2) whose roles in B-cell differentiation are poorly defined. We found that a new class of ATP-competitive mTOR kinase inhibitors (TOR-KIs) can augment antibody class switching at concentrations that partially inhibit mTOR activity. Mechanistic studies indicate that mTORC1 loss suppresses, whereas mTORC2 loss promotes, class switching. The dominant effect of TOR-KIs is to promote switching through mTORC2 inhibition. These findings establish distinct immunomodulatory activity of TOR-KIs compared with the canonical mTOR inhibitor rapamycin.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Rapamycin/sirolimus is a macrolide immunosuppressant that inhibits T and B cell activation and induce Tregs through targeting mTOR (38).”
From A versatile toolkit for overcoming AAV immunity (2022) · cites this paper as [38]
In the citing paper
“Beneficial downstream effects include Treg generation, suppressing CTL and T helper (TH) activation and at higher doses, B-cell proliferation and differentiation (69–71).”
From Immunomodulation in Administration of RAAV: Preclinical and Clinical Adjuvant Pharmacotherapies (2021) · cites this paper as [69]
Citations
Cites
mTOR Signaling in Growth Control and Disease
Laplante, M., & Sabatini, D. M. (2012) · Cell · doi:10.1016/j.cell.2012.03.017 · Cited by 8,509 · cited 1×
“The mTOR kinase is present in two cellular complexes, mTOR-complex 1 (mTORC1) defined by the raptor subunit and mTOR-complex 2 (mTORC2) defined by rictor (3).”
BackgroundAromatic-dependent Salmonella typhimurium are non-virulent and effective as live vaccines
Hoiseth, S. K., & Stocker, B. A. D. (1981) · Nature · doi:10.1038/291238a0 · Cited by 2,078
FoxOs Are Critical Mediators of Hematopoietic Stem Cell Resistance to Physiologic Oxidative Stress
Tothova, Z., Kollipara, R., Huntly, B. J., Lee, B. H., Castrillon, D. H., Cullen, D. E., McDowell, E. P., Lazo-Kallanian, S., Williams, I. R., Sears, C., et al. (2007) · Cell · doi:10.1016/j.cell.2007.01.003 · Cited by 1,562 · cited 1×
“Mice bearing floxed alleles of Foxo1, Foxo3a, and Foxo4 and the inducible Mx1-Cre transgene (23, 24) were injected two times with polyinosinic:polycytidylic acid (polyI:C) before purification of splenic B cells.”
MethodGuertin, D. A., Stevens, D. M., Thoreen, C. C., Burds, A. A., Kalaany, N. Y., Moffat, J., Brown, M., Fitzgerald, K. J., & Sabatini, D. M. (2006) · Developmental Cell · doi:10.1016/j.devcel.2006.10.007 · Cited by 1,415 · cited 2×
“mTORC2 and AKT function are required for subsequent phosphorylation of forkhead box, subgroup O (FoxO) transcription factors (4, 5).”
BackgroundJacinto, E., Facchinetti, V., Liu, D., Soto, N., Wei, S., Jung, S. Y., Huang, Q., Qin, J., & Su, B. (2006) · Cell · doi:10.1016/j.cell.2006.08.033 · Cited by 1,410 · cited 3×
“mTORC2 and AKT function are required for subsequent phosphorylation of forkhead box, subgroup O (FoxO) transcription factors (4, 5).”
BackgroundMethodRegulation of Immune Responses by mTOR
Powell, J. D., Pollizzi, K. N., Heikamp, E. B., & Horton, M. R. (2012) · Annual Review of Immunology · doi:10.1146/annurev-immunol-020711-075024 · Cited by 836 · cited 1×
“PI3K/AKT signaling and other inputs activate the mammalian target of rapamycin (mTOR), a multifunctional kinase that promotes cell growth, division, and metabolic reprogramming (1, 2).”
BackgroundChresta, C. M., Davies, B. R., Hickson, I., Harding, T., Cosulich, S., Critchlow, S. E., Vincent, J. P., Ellston, R., Jones, D., Sini, P., et al. (2010) · Cancer Research · doi:10.1158/0008-5472.can-09-1751 · Cited by 812 · cited 1×
“2 B and C), we chose AZD8055 for most in vivo experiments because it is well tolerated at a dose with anticancer activity in mice (20 mg·kg·d) (16, 17).”
MethodmTORC1 controls fasting-induced ketogenesis and its modulation by ageing
Sengupta, S., Peterson, T. R., Laplante, M., Oh, S., & Sabatini, D. M. (2010) · Nature · doi:10.1038/nature09584 · Cited by 646 · cited 1×
“013138) and have been described previously (29).”
Immunoglobulin class-switch DNA recombination: induction, targeting and beyond
Xu, Z., Zan, H., Pone, E. J., Mai, T., & Casali, P. (2012) · Nature Reviews Immunology · doi:10.1038/nri3216 · Cited by 460 · cited 1×
“2G), the mutator protein required for initiation of CSR (13).”
BackgroundWander, S. A., Hennessy, B. T., & Slingerland, J. M. (2011) · Journal of Clinical Investigation · doi:10.1172/jci44145 · Cited by 427 · cited 1×
“ATP-competitive mTOR kinase inhibitors (TOR-KIs) block activity of both mTORC1 and mTORC2, and were developed to overcome limitations of rapamycin as anticancer agents (11, 12).”
BackgroundShiota, C., Woo, J.-T., Lindner, J., Shelton, K. D., & Magnuson, M. A. (2006) · Developmental Cell · doi:10.1016/j.devcel.2006.08.013 · Cited by 389
Distinct functions for the transcription factor Foxo1 at various stages of B cell differentiation
Dengler, H. S., Baracho, G. V., Omori, S. A., Bruckner, S., Arden, K. C., Castrillon, D. H., DePinho, R. A., & Rickert, R. C. (2008) · Nature Immunology · doi:10.1038/ni.1667 · Cited by 354 · cited 5×
“The latter observation is consistent with the finding that the PI3K p110δ inhibitor IC87114 does not increase CSR in Foxo1-deficient B cells under IgG1 switching conditions (22).”
BackgroundResultInfluentialEffective and selective targeting of leukemia cells using a TORC1/2 kinase inhibitor
Janes, M. R., Limon, J. J., So, L., Chen, J., Lim, R. J., Chavez, M. A., Vu, C., Lilly, M. B., Mallya, S., Ong, S. T., et al. (2010) · Nature Medicine · doi:10.1038/nm.2091 · Cited by 337 · cited 13×
“Therefore, we assessed the impact of AZD8055 on in vivo humoral responses to NP-OVA in aged mice, using the transient dosing protocol as described above.”
BackgroundMethodResultSelf-citationDelivery of Epitopes by the Salmonella Type III Secretion System for Vaccine Development
Rüssmann, H., Shams, H., Poblete, F., Fu, Y., Galán, J. E., & Donis, R. O. (1998) · Science · doi:10.1126/science.281.5376.565 · Cited by 276
Haynes, L., Eaton, S. M., Burns, E. M., Randall, T. D., & Swain, S. L. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2433717100 · Cited by 270 · cited 1×
“Age-related decreases in immune function can be attributed to defects in the innate and adaptive immune compartments, including humoral immunity (21).”
BackgroundAKT/FOXO Signaling Enforces Reversible Differentiation Blockade in Myeloid Leukemias
Sykes, S. M., Lane, S. W., Bullinger, L., Kalaitzidis, D., Yusuf, R., Saez, B., Ferraro, F., Mercier, F., Singh, H., Brumme, K. M., et al. (2011) · Cell · doi:10.1016/j.cell.2011.07.032 · Cited by 257 · cited 1×
“Mice bearing floxed alleles of Foxo1, Foxo3a, and Foxo4 and the inducible Mx1-Cre transgene (23, 24) were injected two times with polyinosinic:polycytidylic acid (polyI:C) before purification of splenic B cells.”
MethodSelf-citationOmori, S. A., Cato, M. H., Anzelon-Mills, A., Puri, K. D., Shapiro-Shelef, M., Calame, K., & Rickert, R. C. (2006) · Immunity · doi:10.1016/j.immuni.2006.08.015 · Cited by 248 · cited 3×
“Proc Natl Acad Sci USA 100(25):15053–15058.”
BackgroundKaniga, K., Uralil, J., Bliska, J. B., & Galán, J. E. (1996) · Molecular Microbiology · doi:10.1111/j.1365-2958.1996.tb02571.x · Cited by 239
Rolf, J., Bell, S. E., Kovesdi, D., Janas, M. L., Soond, D. R., Webb, L. M. C., Santinelli, S., Saunders, T., Hebeis, B., Killeen, N., et al. (2010) · The Journal of Immunology · doi:10.4049/jimmunol.1001730 · Cited by 227 · cited 4×
“For example, the differentiation of follicular helper T (TFH) cells is known to be influenced by PI3K activity (18).”
BackgroundMethodInfluentialAkt and mTOR in B Cell Activation and Differentiation
Limon, J. J., & Fruman, D. A. (2012) · Frontiers in Immunology · doi:10.3389/fimmu.2012.00228 · Cited by 215 · cited 2×
“PI3K/AKT signaling and other inputs activate the mammalian target of rapamycin (mTOR), a multifunctional kinase that promotes cell growth, division, and metabolic reprogramming (1, 2).”
BackgroundSelf-citationCunningham, A. F., Gaspal, F., Serre, K., Mohr, E., Henderson, I. R., Scott-Tucker, A., Kenny, S. M., Khan, M., Toellner, K.-M., Lane, P. J. L., et al. (2007) · The Journal of Immunology · doi:10.4049/jimmunol.178.10.6200 · Cited by 210 · cited 1×
“The early humoral response to Salmonella in C57BL/6 mice is dominated by IgM antibodies and an extrafollicular IgG2c response, with GCs delayed until several weeks after infection (19, 20).”
BackgroundKeating, R., Hertz, T., Wehenkel, M., Harris, T. L., Edwards, B. A., McClaren, J. L., Brown, S. A., Surman, S., Wilson, Z. S., Bradley, P., et al. (2013) · Nature Immunology · doi:10.1038/ni.2741 · Cited by 193
Amiel, E., Everts, B., Freitas, T. C., King, I. L., Curtis, J. D., Pearce, E. L., & Pearce, E. J. (2012) · The Journal of Immunology · doi:10.4049/jimmunol.1103741 · Cited by 175 · cited 1×
“However, AZD8055 was reported to enhance innate immune activation to promote anticancer immune responses (26); therefore, mTOR inhibition might augment immune responses, in part, through stimulating inflammatory cytokine production (27, 28).”
BackgroundThe dual mTORC1 and mTORC2 inhibitor AZD8055 has anti-tumor activity in acute myeloid leukemia
Willems, L., Chapuis, N., Puissant, A., Maciel, T. T., Green, A. S., Jacque, N., Vignon, C., Park, S., Guichard, S., Herault, O., et al. (2012) · Leukemia · doi:10.1038/leu.2011.339 · Cited by 159 · cited 1×
“2 B and C), we chose AZD8055 for most in vivo experiments because it is well tolerated at a dose with anticancer activity in mice (20 mg·kg·d) (16, 17).”
MethodInhibition of Human B Lymphocyte Cell Cycle Progression and Differentiation by Rapamycin
Aagaard-Tillery, K. M., & Jelinek, D. F. (1994) · Cellular Immunology · doi:10.1006/cimm.1994.1193 · Cited by 126 · cited 2×
“The suppression of both differentiation pathways is consistent with early studies of rapamycin action in B cells (8).”
BackgroundResultDonahue, A. C., & Fruman, D. A. (2003) · The Journal of Immunology · doi:10.4049/jimmunol.170.12.5851 · Cited by 122 · cited 1×
“track proliferation was performed as described elsewhere (32).”
MethodSelf-citationB Cell–Specific Deficiencies in mTOR Limit Humoral Immune Responses
Zhang, S., Pruitt, M., Tran, D., du Bois, W., Zhang, K., Patel, R. S., Hoover, S. B., Simpson, R. M., Simmons, J. K., Gary, J. M., et al. (2013) · The Journal of Immunology · doi:10.4049/jimmunol.1201767 · Cited by 102 · cited 3×
“Conditional deletion of the mTOR gene in mouse B cells strongly impairs proliferation and GC differentiation (6).”
BackgroundDonahue, A. C., & Fruman, D. A. (2007) · European Journal of Immunology · doi:10.1002/eji.200737281 · Cited by 94 · cited 1×
“Although AKT can promote mTORC1 activity (multiple arrows), inhibition of PI3K/AKT does not completely suppress mTORC1 signaling in activated B cells (36).”
BackgroundSelf-citationJiang, Q., Weiss, J. M., Back, T. C., Chan, T., Ortaldo, J. R., Guichard, S. M., & Wiltrout, R. H. (2011) · Cancer Research · doi:10.1158/0008-5472.can-10-3968 · Cited by 86 · cited 2×
“Nunc Maxisorp plates were coated at a concentration of 10 μg/mL in a 50-μL total volume with NP(26)-BSA or NP(5)-BSA (Biosearch Technologies) for high-affinity antibody discrimination.”
BackgroundMethodRequirement for Rictor in homeostasis and function of mature B lymphoid cells
Lee, K., Heffington, L., Jellusova, J., Nam, K. T., Raybuck, A. L., Cho, S. H., Thomas, J. W., Rickert, R. C., & Boothby, M. R. (2013) · Blood · doi:10.1182/blood-2013-01-477505 · Cited by 77 · cited 3×
“Inactivation of mTORC2 in B cells, via rictor deletion, reduces mature B-cell survival and impairs antibody responses and GC formation (7).”
BackgroundMethodInfluentialGenetic or pharmaceutical blockade of p110δ phosphoinositide 3-kinase enhances IgE production
Zhang, T., Okkenhaug, K., Nashed, B. F., Puri, K. D., Knight, Z. A., Shokat, K. M., Vanhaesebroeck, B., & Marshall, A. J. (2008) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2008.08.008 · Cited by 72 · cited 1×
“As reported previously (14, 15), inhibiting PI3K strongly induced switching to IgE with lesser effects of AKT inhibition (Fig.”
BackgroundImmune Regulation by Rapamycin: Moving Beyond T Cells
Janes, M. R., & Fruman, D. A. (2009) · Science Signaling · doi:10.1126/scisignal.267pe25 · Cited by 57 · cited 1×
“However, AZD8055 was reported to enhance innate immune activation to promote anticancer immune responses (26); therefore, mTOR inhibition might augment immune responses, in part, through stimulating inflammatory cytokine production (27, 28).”
BackgroundSelf-citationTargeting TOR dependence in cancer
Janes, M. R., & Fruman, D. A. (2010) · Oncotarget · doi:10.18632/oncotarget.110 · Cited by 48 · cited 1×
“ATP-competitive mTOR kinase inhibitors (TOR-KIs) block activity of both mTORC1 and mTORC2, and were developed to overcome limitations of rapamycin as anticancer agents (11, 12).”
BackgroundSelf-citationHoughton, P. J., Gorlick, R. G., Kolb, E. A., Lock, R. B., Carol, H., Morton, C. L., Keir, S. T., Reynolds, C. P., Kang, M. H., Phelps, D. A., et al. (2011) · Pediatric Blood & Cancer · doi:10.1002/pbc.22935 · Cited by 41 · cited 1×
“Formulation of AZD8055 has been described previously (31).”
BackgroundMatsiota-Bernard, P., Mahana, W., Avraméas, S., & Nauciel, C. (1993) · PubMed Central · Cited by 35
p110δ Phosphoinositide 3-Kinase Represses IgE Switch by Potentiating BCL6 Expression
Zhang, T., Makondo, K. J., & Marshall, A. J. (2012) · The Journal of Immunology · doi:10.4049/jimmunol.1103302 · Cited by 32 · cited 1×
“As reported previously (14, 15), inhibiting PI3K strongly induced switching to IgE with lesser effects of AKT inhibition (Fig.”
Background
Cited by
The PI3K Pathway in Human Disease
Fruman, D. A., Chiu, H., Hopkins, B. D., Bagrodia, S., Cantley, L. C., & Abraham, R. T. (2017) · Cell · doi:10.1016/j.cell.2017.07.029 · Cited by 2,749
“Similarly, inactivation of mTORC2 or AKT promotes class switching in a FOXO-depen-dent manner (Limon et al., 2014).”
Self-citationGerminal Center Selection and Affinity Maturation Require Dynamic Regulation of mTORC1 Kinase
Ersching, J., Efeyan, A., Mesin, L., Jacobsen, J. T., Pasqual, G., Grabiner, B. C., Dominguez-Sola, D., Sabatini, D. M., & Victora, G. D. (2017) · Immunity · doi:10.1016/j.immuni.2017.06.005 · Cited by 308
“…been linked to T cell differentiation, tolerance, anergy, and migration (Araki et al., 2009; Sinclair et al., 2008; Zeng et al., 2013; Zheng et al., 2007), as well as to B cell differentiation and antibody production (Jones et al., 2016; Limon et al., 2014; Lin et al., 2015; Omori et al., 2006).”
Metabolic Regulation of the Immune Humoral Response
Boothby, M., & Rickert, R. C. (2017) · Immunity · doi:10.1016/j.immuni.2017.04.009 · Cited by 247
“However, BCR signaling and downstream activation of the PI3K pathway, including both mTORC1 and mTORC2, modulates CSR and the propensity to form plasma cells (Jones et al., 2016; Keating et al., 2013; Limon et al., 2014; Omori et al., 2006).”
BackgroundMitochondrial function in immune cells in health and disease
Faas, M. M., & de Vos, P. (2020) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2020.165845 · Cited by 246
MenTORing Immunity: mTOR Signaling in the Development and Function of Tissue-Resident Immune Cells
Jones, R. G., & Pearce, E. J. (2017) · Immunity · doi:10.1016/j.immuni.2017.04.028 · Cited by 212
Metadata
- Authors
- Limon, J. J., So, L., Jellbauer, S., Chiu, H., Corado, J., Sykes, S. M., Raffatellu, M., & Fruman, D. A.
- Affiliations
- Department of Molecular Biology & Biochemistry,
- University of California, Irvine (US)
- Fox Chase Cancer Center (US)
- Venue
- Proceedings of the National Academy of Sciences
- Publisher
- National Academy of Sciences
- Published
- 2014-11-10
- Volume
- 111
- Issue
- 47
- Pages
- E5076-85
- ISSN
- 0027-8424 (ISSN-L)
- 1091-6490
- PMC
- PMC4250172
- OpenAlex
- W2002368085
- Cited by
- 76
- References
- 36
- Citations by year
- 2026: 5 · 2025: 8 · 2024: 2 · 2023: 8 · 2022: 6 · 2021: 3 · 2020: 6 · 2019: 2 · 2018: 8 · 2017: 17 · 2016: 9 · 2015: 2
- FWCI
- 4.26
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Proceedings of the National Academy of Sciences (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- eScholarship (California Digital Library) (submittedVersion, cc-by)
- Funders
- National Institutes of Health
- National Cancer Institute (P30 CA 62203, R00CA158461, P30CA062203)
- National Institute of Allergy and Infectious Diseases (R21AI099656, R01AI083663, T32AI060573, R03AI085462)
- Topics
- Life Sciences › Immunology and Microbiology › Immunology › T-cell and B-cell Immunology
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › PI3K/AKT/mTOR signaling in cancer
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Signaling Pathways in Disease
- Keywords
- mTOR inhibitors, mTORC1, mTORC2, antibody class switching, B cells, FOXO transcription factors, AZD8055, rapamycin, germinal center, somatic hypermutation, B cell differentiation, high-affinity antibodies, vaccination
- MeSH terms
- Mechanistic Target of Rapamycin Complex 2, Allosteric Regulation, Animals, Immunoglobulin G, Mice, Inbred C57BL, Immunoglobulin Class Switching, Sirolimus, Multiprotein Complexes, Protein Kinase Inhibitors, Mice, TOR Serine-Threonine Kinases
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.